Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

被引：0
|
作者：
Vimalanand S. Prabhu
Joseph S. Solomkin
Goran Medic
Jason Foo
Rebekah H. Borse
Teresa Kauf
Benjamin Miller
Shuvayu S. Sen
Anirban Basu
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] University of Cincinnati College of Medicine,undefined
[4] Mapi Group,undefined
[5] Baxalta US Inc.,undefined
[6] Shire,undefined
[7] Pharmaceutical Outcomes Research and Policy Program,undefined
[8] University of Washington,undefined
[9] Center for Observational and Real World Evidence (CORE),undefined
[10] Merck & Co.,undefined
[11] Inc.,undefined
来源：
Antimicrobial Resistance & Infection Control | / 6卷
关键词：
Cost-effectiveness analysis; Ceftolozane; Piperacillin; Tazobactam; Intraabdominal infections; United States; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 16 条
  • [1] Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
    Prabhu, Vimalanand S.
    Solomkin, Joseph S.
    Medic, Goran
    Foo, Jason
    Borse, Rebekah H.
    Kauf, Teresa
    Miller, Benjamin
    Sen, Shuvayu S.
    Basu, Anirban
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2017, 6
  • [2] COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM PLUS METRONIDAZOLE AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN COLOMBIA
    Lasalvia, P.
    Rosselli, D.
    Castaneda-Cardona, C.
    Garzon, J.
    Hernandez, F.
    Beltran, C.
    Rojas, M.
    Lopez, M. C.
    Sarpong, E. M.
    VALUE IN HEALTH, 2018, 21 : S152 - S153
  • [3] Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
    Prabhu, Vimalanand
    Foo, Jason
    Ahir, Harblas
    Sarpong, Eric
    Merchant, Sanjay
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 840 - 849
  • [4] Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
    Kauf, Teresa L.
    Prabhu, Vimalanand S.
    Medic, Goran
    Borse, Rebekah H.
    Miller, Benjamin
    Gaultney, Jennifer
    Sen, Shuvayu S.
    Basu, Anirban
    BMC INFECTIOUS DISEASES, 2017, 17
  • [5] Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
    Teresa L Kauf
    Vimalanand S. Prabhu
    Goran Medic
    Rebekah H. Borse
    Benjamin Miller
    Jennifer Gaultney
    Shuvayu S. Sen
    Anirban Basu
    BMC Infectious Diseases, 17
  • [6] COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS IN COLOMBIA
    Lasalvia, P.
    Rosselli, D.
    Castaneda-Cardona, C.
    Garzon, J.
    Hernandez, F.
    Beltran, C.
    Rojas, M.
    Lopez, M. C.
    Sarpong, E. M.
    VALUE IN HEALTH, 2018, 21 : S152 - S152
  • [7] Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery
    Maltezou, HC
    Nikolaidis, P
    Lebesii, E
    Dimitriou, L
    Androulakakis, E
    Kafetzis, DA
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (09) : 643 - 646
  • [8] Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery
    Maltezou H.
    Nikolaidis P.
    Lebesii E.
    Dimitriou L.
    Androulakakis E.
    Kafetzis D.
    European Journal of Clinical Microbiology and Infectious Diseases, 2001, 20 (9): : 643 - 646
  • [9] Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China
    Shi, Xiaoping
    Fu, Jie
    Li, Xiaoyu
    Lv, Qianzhou
    Wan, Xu
    Xu, Qing
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2023, 16 (03) : 361 - 367
  • [10] COST-EFFECTIVENESS ANALYSIS OF TIGECYCLINE IN COMPARISION WITH IMIPENEM/CILASTATIN OR PIPERACILLIN/TAZOBACTAM IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS: A PERSPECTIVE OF IRANIAN HEALTH SYSTEMS
    Taheri, S.
    Mohammadzadeh, H.
    Mehralian, G.
    VALUE IN HEALTH, 2017, 20 (09) : A789 - A789
12